Curated News
By: NewsRamp Editorial Staff
November 06, 2025
Sigyn Therapeutics Unveils CardioDialysis to Combat Heart Disease
TLDR
- Sigyn Therapeutics' CardioDialysis offers dialysis clinics a new $2.8 billion revenue stream by extending ESRD patient lives while reducing cardiovascular mortality.
- CardioDialysis uses existing dialysis machines to remove inflammatory molecules and cholesterol-transporting lipoproteins through broad-spectrum blood purification during regular treatments.
- CardioDialysis could transform dialysis clinics into treatment centers that extend patient lives and reduce cardiovascular deaths among vulnerable ESRD populations.
- CardioDialysis leverages 7,500 existing dialysis clinics to treat cardiovascular disease with a device approach proven to reduce major cardiac events by 59-95%.
Impact - Why it Matters
This development matters because cardiovascular disease remains the world's leading cause of death, and current pharmaceutical treatments have significant limitations, particularly for vulnerable populations like dialysis patients who face mortality rates exceeding 67% from heart-related complications. The CardioDialysis approach represents a paradigm shift in cardiovascular care by leveraging existing dialysis infrastructure to deliver broad-spectrum treatment that could substantially reduce major adverse cardiovascular events. For the millions of people at risk of cardiovascular disease and the 550,000 Americans receiving regular dialysis treatments, this technology offers hope for extended life expectancy and improved quality of life. The potential to transform dialysis clinics into comprehensive treatment centers could revolutionize how we manage cardiovascular health in high-risk populations while creating substantial economic value for healthcare providers and patients alike.
Summary
Sigyn Therapeutics, a medical technology company developing dialysis-like therapies, has announced a strategic pivot toward cardiovascular disease treatment with its innovative CardioDialysis™ device. In a shareholder letter from CEO-Inventor Jim Joyce, the company revealed it has filed a trademark application for CardioDialysis™ and is prioritizing this therapy over previous indications. The device represents a groundbreaking approach to treating cardiovascular disease, which remains the leading cause of death globally, by leveraging a broad-spectrum mechanism that targets multiple inflammatory molecules and cholesterol-transporting lipoproteins simultaneously. This multi-target strategy aims to overcome the limitations of single-target pharmaceutical drugs like statins, potentially offering superior protection against Major Adverse Cardiovascular Events (MACE) in a market exceeding $100 billion annually.
The initial clinical focus will target end-stage renal disease (ESRD) patients undergoing dialysis, a population where cardiovascular disease accounts for a staggering 67% of deaths according to U.S. Renal Data System statistics. CardioDialysis™ offers significant advantages by being deployable on existing dialysis machines within the more than 7,500 dialysis clinics across the United States, eliminating the infrastructure constraints that have limited similar therapies like Lipoprotein Apheresis. The company cites FDA-approved precedent showing that blood purification devices can reduce MACE by 59-95%, significantly outperforming pharmaceutical statins that typically reduce MACE by only 20-45%. This strategic approach also addresses the unique challenges ESRD patients face, including elevated lipoprotein(a) levels and dialysis-induced inflammatory responses that current pharmaceuticals cannot adequately treat.
From a regulatory and commercial perspective, Sigyn Therapeutics highlights the efficiency of conducting clinical studies in dialysis clinics rather than hospital ICUs, noting that ESRD patients already have established blood access and stable conditions ideal for clinical trials. The company is currently editing its Investigational Device Exemption submission to clearly define cardiovascular disease as the treatment indication. Beyond the immediate patient benefits of extended life and improved quality, CardioDialysis™ could transform dialysis clinics into combined Renal and CardioDialysis treatment centers, potentially generating billions in additional revenue for the dialysis industry while recapturing lost treatment revenues when patients are hospitalized. To learn more about Sigyn Therapeutics, visit their website at www.SigynTherapeutics.com, which provides additional information about their development pipeline including ImmunePrep™, ChemoPrep™, and ChemoPure™ therapies for cancer treatment.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Sigyn Therapeutics Unveils CardioDialysis to Combat Heart Disease
